1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

$Thumbnail for Clinical Efficacy of the Novel Oral NEK7 Inflammasome Inhibitor Ofirnoflast in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndromes With High-Risk Mutational Profiles: A Case Series$

MDS - 1093

Clinical Efficacy of the Novel Oral NEK7 Inflammasome Inhibitor Ofirnoflast in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndromes With High-Risk Mutational Profiles: A Case Series

Jeremiah Bearss

Poster Presenter: Jeremiah Bearss

Thumbnail for Elevated Interleukin 1ί and Reduced Interleukin 5 in Low-Risk Myelodysplastic Syndromes with Grade 2 or Higher Bone Marrow Fibrosis

MDS - 1103

Elevated Interleukin 1ί and Reduced Interleukin 5 in Low-Risk Myelodysplastic Syndromes with Grade 2 or Higher Bone Marrow Fibrosis

Maria Stella Martino

Poster Presenter: Maria Stella Martino

MDS - 1116

“STAG2-Mutated MDS: Not Only Loss-of-Function?"

Gloria Andreossi

Poster Presenter: Gloria Andreossi

Thumbnail for Mortality Trends Due to Myelodysplastic Syndrome-Associated Anemia in the United States(1999-2024): A 25- Year Retrospective Analysis With Future Projections to 2035

MDS - 1117

Mortality Trends Due to Myelodysplastic Syndrome-Associated Anemia in the United States(1999-2024): A 25- Year Retrospective Analysis With Future Projections to 2035

Pakeeza Saif

Poster Presenter: Pakeeza Saif

MDS - 1120

Defining the Clinicogenomic Footprint of PPM1D in Therapy-Related Myeloid Neoplasms

Fidel Cai

Poster Presenter: Fidel Cai

Thumbnail for First-Line (1L) Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) for Anemia in Lower-Risk Myelodysplastic Syndromes (LR-MDS): A Real-World Analysis from Florida Cancer Specialists & Research Institute (FCS)

MDS - 1121

First-Line (1L) Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) for Anemia in Lower-Risk Myelodysplastic Syndromes (LR-MDS): A Real-World Analysis from Florida Cancer Specialists & Research Institute (FCS)

Amanda Warner

Poster Presenter: Amanda Warner

Thumbnail for Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

MDS - 113

Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Guillermo Garcia-Manero

Poster Presenter: Guillermo Garcia-Manero

Thumbnail for Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program

MDS - 1159

Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program

Silvia Sanz, Nick Kuypers

Poster Presenter: Nick Kuypers

Thumbnail for Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

MDS - 1167

Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

Nick Kuypers

Poster Presenter: Nick Kuypers